Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary

Transcription

1 Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit (with a preferred option) OBJECTIVE The intent of the Biologic Immunomodulators Prior Authorization with Quantity Limit criteria is to ensure that patients prescribed therapy are properly selected according to Food and Drug Administration (FDA)-approved product labeling and/or clinical guidelines and/or clinical trials. The criteria will encourage the use of first-line conventional, some of which are available as generics (for example, first-line for arthritis indications, methotrexate and leflunomide, are both available as generics). If a plan has preferred criteria will also encourage use of two preferred biologic immunomodulators when clinically appropriate before the nonpreferred with appropriate dosing. This program allows continuation of therapy when patients have been receiving and are stabilized on a biologic immunomodulator. TARGET AGENTS Disease State Try/Fail Preferred Non-preferred Rheumatoid Arthritis (RA) Enbrel, Humira, Simponi Psoriatic Arthritis Plaque Psoriasis Ankylosing Spondylitis **Crohn s Disease Ulcerative Colitis PJIA HS Uveitis ; then must try Xeljanz (XR) prior to any other non-preferred agent (last preferred agent is still approvable prior to Xeljanz (XR)) Try/Fail 3 preferred Try/Fail 3 preferred Try/Fail 3 preferred Try/Fail 1 preferred agent Try/Fail 1 preferred agent Enbrel, Humira, Cosentyx, Simponi, Stelara Enbrel, Humira, Cosentyx, Stelara Cosentyx, Enbrel, Humira, Simponi Humira, Stelara Humira, Simponi Enbrel, Humira Humira Humira Actemra, Cimzia, Inflectra, Kevzara, Kineret, Orencia, Remicade, Renflexis, Simponi ARIA, Xeljanz (XR) Cimzia, Inflectra, Orencia, Remicade, Renflexis, Simponi ARIA, Xeljanz (XR) Inflectra, Remicade, Renflexis, Siliq, Taltz, Tremfya Cimzia, Inflectra, Remicade, Renflexis, Simponi ARIA Cimzia, Entyvio, Inflectra, Remicade, Renflexis Entyvio, Inflectra, Remicade, Renflexis Actemra, Orencia N/A N/A HCSC_CS_Biologic_Immunomodulators_PAQL_ProgSum_AR0817_r0318 Page 1 of 6 Divisions of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association

2 SJIA, CAPS/NOMID, CRS N/A N/A N/A **infliximab (Remicade) and infliximab biosimilars (e.g., Inflectra, Renflexis) are the only FDA approved drugs for fistulizing Crohn s Disease- preferreds are not FDA approved for this subindication and do not apply QUANTITY LIMITS F TARGET AGENTS Brand (generic) GPI Quantity Limit Multisource Code Actemra (tocilizumab) 162 mg/0.9 ml E520 4 s/28 days Cimzia (certolizumab) 2 x 200 mg vial, kit kit/28 days (1 kit of 2 x 200 mg vials/28 days) 2 x 200 mg/ml, kit kit/28 days (1 kit of 2 s/28 days) 6 X 200 mg/ml, starter kit starter kit/180 days Cosentyx TM (secukinumab) 150 mg/ml autoinjector injectors/28 days D520 1 package of mg/ml autoinjector D520 1 injector/28 days 150 mg/ml pre-filled E /28 days 300 mg/2 ml (2 x E520 1 package of mg/ml) pre-filled s/28 days Enbrel (etanercept) 50 mg/ml E530 4 s/28 days 50 mg/ml SureClick 4 autoinjections/ D530 autoinjector days 50 mg/ml Mini E230 4 injectors/28 days injector 25 mg/0.5 ml E525 8 s/28 days 25 mg/vial, kit vials/28 days Entyvio (vedolizumab) 300 mg/vial vial/56 days Humira (adalimumab) 10 mg/0.2 ml F805 2 s/28 days Ped Crohn s Starter Kit 40 mg/0.8ml (Both 3 and F820 1 kit/180 days pack) 20 mg/0.4 ml, kit F810 2 s/28 days 40 mg/0.8 ml, kit F820 2 s/28 days 40 mg/0.8 ml pen, kit F420 2 pens (kits)/28 days 40 mg/0.8 ml pen, psoriasis Starter kit F420 1 kit/180 days 40 mg/0.8 ml pen, Crohn s Starter kit F420 1 kit/180 days Kevzara (sarilumab) HCSC_CS_Biologic_Immunomodulators_PAQL_ProgSum_AR0817_r0318 Page 2 of 6

3 Brand (generic) GPI Quantity Limit Multisource Code 150 mg/1.14 ml E520 2 s/28 days 200 mg/1.14 ml E530 2 s/28 days Kineret (anakinra) 100 mg ****** 30 s/30 days Orencia (abatacept) 50 mg/0.4 ml (subcutaneous) E510 4 s/28 days prefilled 87.5 mg/ 0.7 ml E515 4 s/28 days 125 mg/ml (subcutaneous) prefilled E520 4 s/28 days 125 mg/ml (subcutaneous) ClickJect autoinjector Siliq (brodalumab) 210 mg/1.5 ml D520 4 autoinjectors/28 days E520 2 s/28 days Simponi (golimumab) 50 mg/0.5 ml E520 1 /28 days 50 mg/0.5 ml autoinjector D520 1 /28 days 100 mg/1 ml E540 1 /28 days 100 mg/1 ml autoinjector D540 1 /28 days Stelara (ustekinumab) 130 mg/26 ml (5 mg/ml) vials/180 days 45 mg/0.5 ml E /84 days 90 mg/1 ml E540 1 /56 days Taltz (ixekizumab) 80 mg/ml autoinjector D520 1 /28 days 80 mg/ml prefilled E520 1 /28 days Tremfya (guselkumab) 100 mg/ml prefilled E520 1 ml (1 )/56 days Xeljanz (tofactinib) 5 mg tablet tablets daily Xeljanz XR (tofactinib extended release) 11 mg tablet tablet/day PRI AUTHIZATION CRITERIA F APPROVAL Initial Evaluation Preferred and Nonpreferred will be approved when the following criteria are met: 1. ONE of the following: a. There is documentation that the patient is currently being treated with the requested agent (starting on samples is not approvable) HCSC_CS_Biologic_Immunomodulators_PAQL_ProgSum_AR0817_r0318 Page 3 of 6

4 b. The prescriber states the patient is currently being treated with the requested agent (starting on samples is not approvable) is at risk if therapy is changed c. ALL of the following: i. ONE of the following: 1. The patient s diagnosis is rheumatoid arthrisis (RA) ONE of the following a. The patient has had an inadequate response to maximally tolerated methotrexate (e.g., titrated to 25 mg weekly) for at least 3-months b. The patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to methotrexate c. The patient has had an inadequate response to another conventional agent (e.g., hydroxychloroquine, leflunomide, or sulfasalazine) used in the treatment of RA for at least 3- months d. The patient has a documented intolerance, FDA labeled contraindication or hypersensitivity to another conventional agent for RA e. The patient s medication history indicates use of another biologic immunomodulator agent for RA 2. The patient has an FDA labeled indication or an indication supported in DrugDex with 1, 2a, or 2b level of evidence for the requested agent ONE of the following: 3. The patient s medication history indicates use of another biologic immunomodulator agent Otezla for the same FDA labeled indication or with a DrugDex 1, 2a, or 2b level of evidence indication as the requested agent a. The patient s diagnosis does NOT require a conventional agent prerequisite* b. The patient s medication history indicates use of ONE conventional agent prerequisite* c. The patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to at least ONE conventional agent ii. If the client has preferred, then ONE of the following: 1. The patient s medication history indicates trial and failure of the required amount of preferred based on the requested indication (See Preferred Agent Try and Fail Column) the patient has a documented intolerance (defined as an intolerance to the drug or its excipients, not to the route of administration), FDA labeled contraindication, or hypersensitivity to ALL of the required preferred for the requested indication 2. The request is for a FDA labeled indication that does NOT require a preferred agent HCSC_CS_Biologic_Immunomodulators_PAQL_ProgSum_AR0817_r0318 Page 4 of 6

5 iii. If Stelara 90 mg is requested, ONE of the following: 1. The patient has a diagnosis of psoriasis weighs >100kg the patient has failed (had an inadequate response to) a trial of 45mg for at least 3 months 2. The patient has a dual diagnosis of psoriasis psoriatic arthritis the patient is >100kg 3. The patient has a diagnosis of Crohn s disease 2. The patient is NOT currently being treated with another biologic immunomodulator agent or Otezla 3. The patient does NOT have any FDA labeled contraindication(s) to the requested agent 4. The patient has been tested for latent TB when required by the prescribing information for the requested agent if positive the patient has begun therapy for active TB 5. ONE of the following: a. The quantity (dose) requested is within the program limit (FDA approved labeled dosage) b. The quantity (dose) requested is greater than the maximum dose recommended in FDA approved labeling, and the prescriber has submitted documentation in support of therapy with a higher dose for the intended diagnosis which has been reviewed and approved by the Clinical Review pharmacist *NOTE: Conventional agent required for diagnoses of rheumatoid arthritis, juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, psoriatic arthritis, psoriasis, ulcerative colitis, uveitis, Crohn s disease, and giant cell arteritis Length of approval: 12 months for all EXCEPT Humira (adalimumab) for ulcerative colitis (UC), Siliq for plaque psoriasis (PS), and the with indications that require loading doses for new starts. For that require a loading dose for a new start, approve the loading dose noted in the table and also the maintenance dose for the remainder of the 12 months. Humira for UC may be approved for 12 weeks and Siliq for PS for 16 weeks. Renewal Evaluation Preferred and Nonpreferred will be approved when the following criteria are met: 1. The patient has been previously approved for the requested agent through Prime Therapeutics PA process (*please note Stelara renewal must be for the same strength as the initial approval) 2. The patient has shown clinical improvement (i.e. slowing of disease progression or decrease in symptom severity and/or frequency) 3. The patient does NOT have any FDA labeled contraindication(s) to the requested agent 4. The patient is NOT currently being treated with another biologic immunomodulator agent or Otezla 5. ONE of the following: A. The quantity (dose) requested is within the program set limit (FDA approved labeled dosage) HCSC_CS_Biologic_Immunomodulators_PAQL_ProgSum_AR0817_r0318 Page 5 of 6

6 B. The quantity (dose) requested is greater than the maximum dose recommended in FDA approved labeling, and the prescriber has submitted documentation in support of therapy with a higher dose for the intended diagnosis which has been reviewed and approved by the Clinical Review pharmacist Length of approval: 12 months for all. HCSC_CS_Biologic_Immunomodulators_PAQL_ProgSum_AR0817_r0318 Page 6 of 6